Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01915602 | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 14 | BayerINDUSTRY | 21 | Apr 8, 2021 | clinicaltrials |
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer(MATEO) | completed | Phase 2 | 242 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01967823 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer |
| completed |
| Phase 2 |
| 11 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Mar 24, 2021 |
| clinicaltrials |
| NCT03389126 | Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment(AvelumabHCC) | completed | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum(NORMAL-R) | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT00061932 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03083613 | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 41 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01972672 | The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 70 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02234596 | Nintedanib in Patients With Advanced Esophagogastric Cancer | completed | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT01246986 | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | completed | Phase 2 | 204 | Eli Lilly and CompanyINDUSTRY | 7 | Jan 12, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01687673 | Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT01264705 | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | completed | Phase 1 / Phase 2 | 47 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02658019 | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | Lynn Feun, MDOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03380130 | A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC(NASIR-HCC) | completed | Phase 2 | 41 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01208103 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01935700 | Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma | completed | Phase 2 | 15 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT01222689 | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02560779 | Trial of TRC105 and Sorafenib in Patients With HCC | completed | Phase 1 / Phase 2 | 27 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jul 17, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT03575806 | Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT01896869 | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 83 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT01775501 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02716766 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03578874 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | completed | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 | clinicaltrials |
| NCT01674309 | First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT03203005 | IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute, NaplesOTHER | 5 | Feb 5, 2020 | clinicaltrials |
| NCT02409524 | An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects | completed | Phase 2 | 15 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01334112 | Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma(AXITINIB) | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00515411 | Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 111 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02749136 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT02854839 | A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma | completed | Phase 2 | 78 | GC Cell CorporationINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01850368 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion | completed | Phase 2 | 35 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01850667 | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | completed | Phase 2 | 74 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT03516071 | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | completed | Phase 2 | 90 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT03939975 | Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC | completed | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2021source: clinicaltrials